Want to see GB:ZTF full AI Analyst Report?
Top Page
Zotefoams
(LSE:ZTF)
Select Model
Select Model
Rating:70Outperform
Price Target:
483.00 p
â–²(16.39% Upside)
Action:Upgraded
Date:03/19/26
The score is driven primarily by attractive valuation (low P/E with a ~2% yield) and a solid financial rebound in 2025 with moderate leverage. These positives are tempered by weak technicals, with the stock trading below key moving averages and bearish momentum indicators.
Positive Factors
Revenue Scaling
Sustained revenue growth over multiple years indicates widening adoption of Zotefoams' specialty foams across end markets. Larger scale supports fixed-cost absorption, funds qualification cycles for aerospace/transport, and underpins long-term investment in product development and capacity.
Negative Factors
Earnings Volatility
Profitability has shown material swings year-to-year, indicating sensitivity to costs, mix or one-offs. This volatility makes forecasting and capital allocation harder, raises the bar for maintaining investor confidence, and can complicate long-term contracts in regulated end markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scaling
Sustained revenue growth over multiple years indicates widening adoption of Zotefoams' specialty foams across end markets. Larger scale supports fixed-cost absorption, funds qualification cycles for aerospace/transport, and underpins long-term investment in product development and capacity.
Read all positive factors
Zotefoams (ZTF) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£215.91M
Dividend Yield2%
Average Volume (3M)76.93K
Price to Earnings (P/E)9.5
Beta (1Y)1.38
Revenue Growth7.24%
EPS GrowthN/A
CountryUK
Employees679
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)0.46
Shares Outstanding49,646,233
10 Day Avg. Volume64,297
30 Day Avg. Volume76,930
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)1.24
P/FCF Ratio9.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£590.00Price Target Upside42.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.39
Revenue Forecast (FY)£191.88M
Zotefoams Business Overview & Revenue Model
Company Description
Zotefoams plc, established in 1921 and headquartered in Croydon, UK, is a global leader in the manufacturing, distribution, and sale of polyolefin block foams. The company serves markets across the United Kingdom, Continental Europe, North America...
How the Company Makes Money
Zotefoams primarily makes money by manufacturing and selling specialty foam materials and related fabricated products to business customers. Its revenue model is predominantly product sales, where customers pay for (1) standard and semi-standard f...
Zotefoams Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
71
Positive
Cash Flow
69
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 158.49M | 147.79M | 126.97M | 127.37M | 100.75M |
| Gross Profit | 52.90M | 46.13M | 41.05M | 38.73M | 26.57M |
| EBITDA | 30.71M | 12.28M | 23.41M | 22.16M | 15.67M |
| Net Income | 22.64M | -2.75M | 9.24M | 10.01M | 4.38M |
Balance Sheet | |||||
| Total Assets | 227.09M | 174.75M | 175.61M | 170.36M | 159.38M |
| Cash, Cash Equivalents and Short-Term Investments | 13.98M | 10.53M | 6.29M | 10.59M | 8.05M |
| Total Debt | 57.01M | 43.56M | 37.86M | 38.41M | 42.40M |
| Total Liabilities | 97.02M | 65.39M | 59.85M | 60.82M | 61.60M |
| Stockholders Equity | 130.08M | 109.36M | 115.76M | 109.54M | 97.78M |
Cash Flow | |||||
| Free Cash Flow | 21.54M | 11.35M | -702.00K | 14.03M | 3.83M |
| Operating Cash Flow | 35.50M | 25.00M | 7.78M | 21.12M | 10.90M |
| Investing Cash Flow | -36.93M | -13.34M | -8.29M | -7.09M | -6.98M |
| Financing Cash Flow | 4.92M | -7.41M | -3.73M | -11.53M | -4.34M |
Zotefoams Technical Analysis
Positive
415.00
Price Trends
424.93
Positive
402.55
Positive
403.27
Positive
Market Momentum
2.38
Positive
52.50
Neutral
27.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ZTF, the sentiment is Positive. The current price of 415 is below the 20-day moving average (MA) of 435.30, below the 50-day MA of 424.93, and above the 200-day MA of 403.27, indicating a bullish trend. The MACD of 2.38 indicates Positive momentum. The RSI at 52.50 is Neutral, neither overbought nor oversold. The STOCH value of 27.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:ZTF.
Zotefoams Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | £215.91M | 9.54 | 18.25% | 2.00% | 7.24% | ― | |
66 Neutral | £4.09B | 65.71 | 2.82% | 3.45% | 4.38% | -60.87% | |
63 Neutral | £618.24M | -30.87 | -4.95% | 9.48% | -1.24% | -166.15% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
58 Neutral | £919.26M | 23.01 | -6.85% | 1.34% | -21.51% | 7.34% | |
46 Neutral | £252.56M | 122.05 | 0.79% | 2.44% | -0.13% | -82.00% | |
46 Neutral | £135.58M | -0.90 | -16.66% | ― | -12.46% | -116.21% |
* Basic Materials Sector Average
GB:ZTF
Zotefoams
439.00
123.27
39.04%
GB:CRDA
Croda International
2,928.00
181.95
6.63%
GB:ELM
Elementis
161.00
-3.73
-2.26%
GB:ESNT
Essentra
89.10
-11.78
-11.67%
GB:SYNT
Synthomer
82.70
-16.80
-16.88%
GB:VCT
Victrex
710.00
67.49
10.50%
Zotefoams Corporate Events
Executive/Board ChangesRegulatory Filings and Compliance
Zotefoams executives increase holdings via share incentive plan
Positive
Jul 16, 2026
Zotefoams plc has disclosed that Group CEO Ronan Cox and Group CFO Nick Wright have increased their beneficial holdings in the company through its Share Incentive Plan. On 13 July 2026, each purchased 34 partnership shares at £4.45 per share,...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Zotefoams Seeks Shareholder Approval for New Save As You Earn Plan
Positive
Jul 15, 2026
Zotefoams has called a general meeting for 3 August 2026 in London to seek shareholder approval for a new Save As You Earn (SAYE) share plan, which would formalise a structured employee savings and share ownership scheme. The board unanimously sup...
Regulatory Filings and Compliance
Zotefoams Executives Increase Holdings Through Share Incentive Plan
Neutral
Jun 17, 2026
Zotefoams has disclosed that Group CEO Ronan Cox and Group CFO Nick Wright have each purchased 34 partnership shares in the company at £4.32 per share under its Share Incentive Plan, alongside receiving 9 and 8 matching shares respectively fo...
Business Operations and StrategyExecutive/Board Changes
Zotefoams Grants New Performance-Based LTIP Awards to Executives and Senior Management
Positive
May 27, 2026
Zotefoams has granted new performance-based share awards under its 2017 Long Term Incentive Plan to executive directors Ronan Cox and Nick Wright, as well as to selected senior managers. The awards, calculated using a three-day average share price...
Business Operations and StrategyDividendsShareholder Meetings
Zotefoams shareholders back all AGM resolutions and dividend payout
Positive
May 27, 2026
Zotefoams plc reported that all resolutions at its 2026 annual general meeting were approved by shareholders, with 54.8% of the company’s issued share capital voting. Investors backed the 2025 annual report, a final dividend of 5.35p per sha...
Business Operations and StrategyFinancial Disclosures
Zotefoams Delivers Strong Start to 2026 as Global Expansion Offsets Footwear Slowdown
Positive
May 27, 2026
Zotefoams reported a 26% year-on-year revenue increase to £64.1m for the four months to 30 April 2026, driven by robust demand across key markets and the contribution from Overseas Konstellation Company, which offset expected moderation in it...
Business Operations and StrategyShareholder Meetings
Zotefoams Schedules Post-AGM Investor Presentation via Investor Meet Company
Positive
May 12, 2026
Zotefoams plc has announced that Group CEO Ronan Cox and Group CFO Nick Wright will deliver a post-AGM investor presentation via the Investor Meet Company platform on 27 May 2026 at 15:30 BST. The virtual event is open to both existing and potenti...
Executive/Board ChangesRegulatory Filings and Compliance
Zotefoams Grants Deferred Share Awards to Top Executives
Positive
May 11, 2026
Zotefoams has granted new share awards to its senior leadership under the company’s Deferred Bonus Share Plan, aligning executive incentives with shareholder interests. Group CEO Ronan Cox received 36,858 ordinary shares and Group CFO Nick W...
Business Operations and StrategyRegulatory Filings and Compliance
Zotefoams Issues New Shares to Employee Trust, Updates Voting Rights
Neutral
May 7, 2026
Zotefoams plc has conditionally agreed to issue 400,000 new ordinary shares, which will be allotted at par to its 2007 Employee Benefit Trust to satisfy future exercises under the group’s share incentive schemes. Following the transaction an...
DividendsFinancial Disclosures
Zotefoams Confirms Final Dividend for 2025 Financial Year
Positive
Apr 30, 2026
Zotefoams plc, a London-based leader in high-performance foam technology, manufactures lightweight AZOTE polyolefin and ZOTEK high-performance foams for a range of global markets. The group also produces T-FIT advanced insulation using its own cel...
Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Zotefoams Publishes 2025 Annual Report and Calls 2026 AGM
Neutral
Apr 27, 2026
Zotefoams has published its 2025 Annual Report and the notice of its 2026 Annual General Meeting, which will be held in Croydon on 27 May 2026 at 10 a.m. The documents are available on the company’s website, with paper copies sent to shareho...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.